Concepedia

Longitudinal outcomes of obeticholic acid therapy in ursodiol‐nonresponsive primary biliary cholangitis: Stratifying the impact of add‐on fibrates in real‐world practice

Elena Góméz, J.L. Montero, Ezequiel Molina, Luisa Garcı́a-Buey, Marta Casado, Javier Fuentes, Miguel Ángel Simón, Alba Díaz-González, Francisco Jorquera, Rosa M. Morillas,

Alimentary Pharmacology & Therapeutics · 2024 · 12 citations · 36 references

DOIFull text

Open access

Abstract

Triple therapy was superior in achieving therapeutic goals in UDCA-nonresponsive PBC. Decompensation was linked to pre-existing portal hypertension.

References

36

EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis

Gideon M. Hirschfield, Ulrich Beuers, Christophe Corpechot et al. · Journal of Hepatology · 2017 · 1.4K citations · Full text

, , +6

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

Frederik Nevens, Pietro Andreoné, G. Mazzella et al. · New England Journal of Medicine · 2016 · 1.1K citations · Full text

Excellent Long-Term Survival in Patients With Primary Biliary Cirrhosis and Biochemical Response to Ursodeoxycholic Acid

Albert Parés, Llorenç Caballería, Juan Rodés · Gastroenterology · 2006 · 741 citations · Full text

, , +11

β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial

Càndid Villanueva, Agustı́n Albillos, Joan Genescà et al. · The Lancet · 2019 · 638 citations

, , +8

A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis

Christophe Corpechot, Olivier Chazouillères, Alexandra Rousseau et al. · New England Journal of Medicine · 2018 · 567 citations · Full text